Nefrocarnit (Levocarnitine)

Levocarnitine transports long‑chain fatty acids into mitochondria by forming acyl‑carnitine complexes. This enables β‑oxidation of fatty acids, producing ATP and supporting energy metabolism, especially in muscle and cardiac tissues that rely heavily on fatty‑acid oxidation.

The appropriate dose of Nefrocarnit is determined by a qualified healthcare professional based on the patient’s age, clinical condition, and laboratory findings. Prescribers tailor the regimen to achieve optimal therapeutic effect while minimizing any potential risk.

Safety data for levocarnitine in pregnancy and lactation are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the prescriber. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To request Nefrocarnit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Nefrocarnit provides levocarnitine in an oral formulation that meets EU quality standards and is available over‑the‑counter. Compared with some prescription‑only carnitine preparations, it offers convenient dosing without the need for injection, making it suitable for long‑term nutritional support and mild deficiency management.

Store Nefrocarnit below 25 °C in its original packaging, protecting it from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral supplement.

Nefrocarnit is taken orally, usually with water. The exact timing—such as with meals or on an empty stomach—should follow the prescriber’s instructions, which consider the patient’s condition and any concomitant medications.

Serious but rare risks include hypersensitivity reactions (rash, itching, swelling), seizures, and cardiac arrhythmias, particularly at high doses or in patients with pre‑existing cardiac conditions. Any signs of these events require immediate medical attention and discontinuation of the product.

Individuals with known hypersensitivity to levocarnitine or any excipients in the formulation should avoid Nefrocarnit. Patients with severe renal impairment should use it only under medical supervision, and it is not recommended for routine use in pregnancy or breastfeeding without a prescriber’s assessment.